Место лерканидипина в лечении артериальной гипертензии: особенности клинического применения и переносимости


Л.О. Минушкина

В настоящем обзоре суммированы данные об эффективности лерканидипина. Лерканидипин – это дигидропиридиновый блокатор кальциевых каналов 3-го поколения, характеризующийся высокой вазоселективностью, большой длительностью действия и хорошей гипотензивной эффективностью. Высокая липофильность препарата способствует постепенно развивающемуся и длительному гипотензивному эффекту препарата. Это уменьшает риск развития неблагоприятных побочных эффектов при лечении лерканидипином и повышает приверженность больных лечению этим препаратом. В обзоре суммированы данные о гипотензивной эффективности лерканидипина, его органопротективных свойствах. Приведено сопоставление его эффективности с таковой препаратов других групп. Рассмотрены возможности использования препарата пожилыми больными артериальной гипертензией.

Литература


1. Turnbull F. Effects of different blood-pressurelowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomized trials. Lancet 2003;362:1527–35.
2. Чазова И.Е., Ратова Л.Г., Бойцов С.А., Небиеридзе Д.В. Диагностика и лечение артериальной гипертензии (Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов) //Системные гипертензии 2010. № 3. С. 5–27.
3. Alvarez C, Gomez E, Simon M, et al. Differences in lercanidipine systemic exposure when administered
according to labelling: in fasting state and 15 minutes before food intake. Eur J Clin Pharmacol 2012;68(7):1043–47.
4. Zanidip. Summary of product characteristics. Napp Pharmaceuticals Ltd, 2002.
5. Bang LM, Chapman TM, Goa KL. Lercanidipine: a review of its efficacy in the management of hypertension. Drugs 2003;63:2449–72.
6. Meredith PA. Lercanidipine: a novel lipophilic dihydropyridine calcium antagonist with long duration of action and high vascular selectivity. Expert Opin Investig Drugs 1999;8(7):1043–62.
7. Omboni S, Zanchetti A. Antihypertensive efficacy of lercanidipine at 2,5, 5 and 10 mg in mild
to moderate essential hypertensives assessed by clinic and ambulatory blood pressure measurements.
J Hypertens 1998;16:1831–38.
8. Ciro A. Active dose findings for lercanidipine in a doubleblind, placebo-controlled design in patients with mild-to-moderate hypertension. J Cardiovasc Pharmacol 1997; 29(Suppl. 2):21–5.
9. Barrios V, Escobar C, Navarro A, et al. Lercanidipine is an effective and well tolerated antihypertensive drug regardless the cardiovascular risk profile: The LAURA study. Int J Clin Pract 2006;60(11):1364–70.
10. Romito R, Pansini MI, Perticone F, et al. Comparative effect of lercanidipine, felodipine, and nifedipine GITS on blood pressure and heart rate in patients with mild to moderate arterial hypertension: the Lercanidipine in Adults (LEAD) Study. J Clin Hypertens (Greenwich) 2003;5(4):249–53.
11. James IG, Jones A, Davies P. A randomised, double-blind, double-dummy comparison of the efficacy and tolerability of lercanidipine tablets and losartan tablets in patients with mild to moderate essential hypertension. J Hum Hypertens 2002;16(8):605–10.
12. Puig JG, Calvo C, Luurila O, et al. Lercanidipine, enalapril and their combination in the treatment
of elderly hypertensive patients: placebocontrolled, randomized, crossover study with four ABPM. J Hum Hypertens 2007;21(12): 917–24.
13. McClellan KJ, Jarvis B. Lercanidipine: a review of its use in hypertension. Drugs 2000;60(5):1123–40.
14. Poncelet P, Ribstein J, Goullard L, et al. Efficacy and acceptability of lercanidipine are not age dependent in patients with essential hypertension: the AGATE study Ann Cardiol Angeiol (Paris). 2004;53(3):123–30.
15. Ninci MA, Magliocca R, Malliani A. Efficacy and tolerability of lercanidipine in elderly patients with mild to moderate hypertension in a placebo-controlled, double-blind study. J Cardiovasc Pharmacol 1997;29:40–4.
16. Millar-Craig M, Shaffu B, Greenough A, et al. Lercanidipine vs lacidipine in isolated systolic hypertension. J Hum Hypertens 2003;17(11):799–806.
17. Cherubini A, Fabris F, Ferrari E, et al. Comparative effects of lercanidipine, lacidipine, and nifedipine
gastrointestinal therapeutic system on blood pressure and heart rate in elderly hypertensive patients: the ELderly and LErcanidipine (ELLE) study. Arch Gerontol Geriatr. 2003;37(3):203–12.
18. Tisaire-Sonchez J, Roma J, Camacho-Azcargorta I, et al. Assessment of cognitive function in patients with essential hypertension treated with lercanidipine. Vasc Health Risk Manag 2006;2(4):491–98.
19. Luque M, Navarro A, Martell N. Use of Non-Steroidal Anti-Inflammatory Drugs Does Not Modify the Antihypertensive Effect of Lercanidipine in Essential Hypertension Br J Cardiol 2006;13(5):353–59.
20. Dalla Vestra M, Pozza G, Mosca A, et al. Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive Type 2 diabetic patients with microalbuminuria: DIAL study (diabete, ipertensione, albuminuria, lercanidipina). Diabetes Nutr Metab 2004;17(5):259–66.
21. Robles NR, Romero B, de Vinuesa EG. Treatment of proteinuria with lercanidipine associated with
renin-angiotensin axis-blocking drugs. Ren Fail 2010;32(2):192–97.
22. Robles NR, Ocon J, Gomez CF, et al. Lercanidipine in patients with chronic renal failure: the ZAFRA
study. Ren Fail 2005;27(1):73–80.
23. Topal C, Erkoc R, Sayarlioglu H. Comparative effects of carvedilol and lercanidipine on ultrafiltration
and solute transport in CAPD patients. Ren Fail 2009;31(6):446–51.
24. Taddei S, Virdis A, Ghiadoni L, et al. Calcium antagonist treatment by lercanidipine prevents hyperpolarization in essential hypertension. Hypertension 2003;41(4):950–55.
25. Grassi G, Quarti-Trevano F, Scopelliti F, et al. Effects of long-term lercanidipine or hydrochlorothiazide
administration on hypertensionrelated vascular structural changes. Blood Press 2006;15(5):268–74.
26. Mackenzie IS, McEniery CM, Dhakam Z, et al. Comparison of the effects of antihypertensive
agents on central blood pressure and arterial stiffness in isolated systolic hypertension. Hypertension 2009;54(2):409–13.
27. Veronesi M, Cicero AF, Prandin MG, et al. A prospective evaluation of persistence on antihypertensive
treatment with different antihypertensive drugs in clinical practice. Vasc Health Risk Manag 2007;3:999–1005.
28. Milani G, Ragazzi M, Simonetti GD, et al. Superior palatability of crushed lercanidipine compared with amlodipine among children. Br J Clin Pharmacol 2010;69(2):204–6.
29. Hollenberg NK. Observations on the safety of lercanidipine: adverse event data from placebocontrolled
trials. Am J Hypertens 2002;15:58–9.
30. Makarounas-Kirchmann K, Glover-Koudounas S, Ferrari P. Results of a meta-analysis comparing
the tolerability of lercanidipine and other dihydropyridine calcium channel blockers. . Clin Ther
2009;31(8):1652–63.
31. Chia YC, Yeoh ES, Ng CJ, et al. Efficacy and tolerability of lercanidipine in mild to moderate hypertension among Asians of different ethnic groups. Singapore Med J 2009;50(5):500–55.
32. Barrios V, Escobar C, de la Figuera M, et al. Tolerability of high doses of lercanidipine versus high doses of other dihydropyridines in daily clinical practice: the TOLERANCE Study. Cardiovasc Ther 2008;26(1):2–9.
33. Borghi C, Prandin MG, Dormi A, Ambrosioni E. Study group of the regional Unit of the Italian Society of Hypertension. Improved Tolerability of the dihydropyridine calcium-channel antagonist lercanidipine: the lercanidipine challenge trial.Blood Press 2003;(Suppl. 1):14–21.
34. Burnier M, Gasser UE. Effi cacy and tolerability of lercanidipine in patients with hypertension:
results of a Phase IV study in general practice. Expert Opin Pharmacother 2007;8:2215–23.
35. Fogari R, Mugellini A, Zoppi A, et al. Differential effects of lercanidipine and nifedipine GITS on plasma norepinephrine in chronic treatment of hypertension. Am J Hypertens. 2003 Jul;16(7):596–959.
36. Cicero AF, Gerocarni B, Rosticci M, Borghi C. Blood pressure and metabolic effect of a combination
of lercanidipine with different antihypertensive drugs in clinical practice. Clin Exp Hypertens 2012;34(2):113–17.
37. Cleophas TJ, van Ouwerkerk BM, van der Meulen J, Zwinderman AH. Diabetics with hypertension
not controlled with ACE inhibitors: alternate therapies. Angiology 2001;52:469–75.


Похожие статьи


Бионика Медиа